Characteristics (N=62) | n (%) | |
---|---|---|
Age (years) | ||
Median (range) | 66 (37–93) | |
Sex | ||
Female | 32 (52) | |
Male | 30 (48) | |
Karnowsky PS | ||
Median (range) | 40 (20–80) | |
≤ 40 | 32 (52) | |
≥ 50 | 30 (48) | |
Site* | ||
Bladder | 10 (16) | |
Lung (NSCLC) | 9 (15) | |
Endometrial | 8 (13) | |
Prostate | 6 (10) | |
Cervical | 6 (10) | |
Gastric | 6 (10) | |
Ovarial | 6 (10) | |
Colorectal | 3 (5) | |
Others# | 8 (13) | |
Histology+ | ||
Adenocarcinoma | 38 (65) | |
Squamous cell carcinoma | 6 (10) | |
Transitional cell carcinoma | 9 (15) | |
Others | 6 (10) | |
Tumor-classification+ | ||
T0 | 2 (3) | |
T3 | 2 (3) | |
T4 | 55 (94) | |
Metastasis+ | ||
No | 1 (2) | |
Yes | 52 (88) | |
Unknown | 6 (10) | |
Liver metastasis+ | ||
No | 43 (73) | |
Yes | 16 (27) | |
Bleeding Site+ | ||
Primary tumor | 48 (81) | |
Metastasis | 11 (19) | |
Symptom | ||
Vaginal bleeding | 19 (31) | |
Hematuria | 17 (27) | |
Hemoptysis | 10 (16) | |
Others | 16 (26) | |
First diagnosis to hRT (months) | ||
Median (range) | 11 (0.3-183) |